Scientific Regulatory Policy Committee Points to Consider*: Nuisance Factors, Block Effects, and Batch Effects in Nonclinical Safety Assessment Studies. (June 2020)

• Record Type: Journal Article
• Authors: Schultze, Albert Eric; Bennet, Bindu; Rae, Jessica Caverly; Chiang, Alan Y.; Frazier, Kendall; Katavolos, Paula; McKinney, LuAnn; Patrick, Daniel J.; Tripathi, Niraj
• Is Part Of: Toxicologic pathology. Volume 48:Number 4(2020)
• Page Start: 537
• Page End: 548
• Publication Date: 2020-06
• Subjects: block effects -- batch effects -- nuisance factors -- study design -- blocking; Pathology -- Periodicals; Toxicology -- Periodicals; Pathology; Toxicology; 615.9
• DOI: 10.1177/0192623320906385
• Languages: English
• ISSNs: 0192-6233

Abstract

Detection of test article–related effects and the determination of the adversity of those changes are the primary goals of nonclinical safety assessment studies for drugs and chemicals in development. During these studies, variables that are not of primary interest to investigators may change and influence data interpretation. These variables, often referred to as "nuisance factors, " may influence other groups of data and result in "block or batch effects" that complicate data interpretation. Definitions of the terms "nuisance factors, " "block effects, " and "batch effects, " as they apply to nonclinical safety assessment studies, are reviewed. Multiple case examples of block and batch effects in safety assessment studies are provided, and the challenges these bring to pathology data interpretation are discussed. Methods to mitigate the occurrence of block and batch effects in safety assessment studies, including statistical blocking and utilization of study designs that minimize potential confounding variables, incorporation of adequate randomization, and use of an appropriate number of animals or repeated measurement of specific parameters for increased precision, are reviewed. *This Points to Consider article is a product of a Society of Toxicologic Pathology (STP) Working Group commissioned by the Scientific and Regulatory Policy Committee (SRPC) of the STP. It has been reviewed and approved by the SRPC and Executive Committee of the STP but it does not represent a formal Best Practice recommendation of the Society; rather, it is intended to provide key "points to consider" in designing nonclinical studies or interpreting data from toxicity and safety studies intended to support regulatory submissions. The points expressed in this document are those of the authors and do not reflect views or policies of the employing institutions. Readers of Toxicologic Pathology are encouraged to send their thoughts on these articles or ideas for new topics to the Editor.